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Abstract
Objective: Recent findings have shown that pharmacogenetic manipulations of
the Ras-ERK pathway provide a therapeutic means to tackle L-3,4-dihydroxy-
phenylalanine (L-DOPA)-induced dyskinesia (LID). First, we investigated
whether a prolonged L-DOPA treatment differentially affected ERK signaling in
medium spiny neurons of the direct pathway (dMSNs) and in cholinergic asp-
iny interneurons (ChIs) and assessed the role of Ras-GRF1 in both subpopula-
tions. Second, using viral-assisted technology, we probed Ras-GRF1 and
Ras-GRF2 as potential targets in this pathway. We investigated how selective
blockade of striatal Ras-GRF1 or Ras-GRF2 expression impacted on LID
(induction, maintenance, and reversion) and its neurochemical correlates.
Methods: We used both Ras-GRF1 knockout mice and lentiviral vectors (LVs)
delivering short-hairpin RNA sequences (shRNAs) to obtain striatum-specific
gene knockdown of Ras-GRF1 and Ras-GRF2. The consequences of these
genetic manipulations were evaluated in the 6-hydroxydopamine mouse model
of Parkinson’s disease. Escalating doses of L-DOPA were administered and then
behavioral analysis with immunohistochemical assays and in vivo microdialysis
were performed. Results: Ras-GRF1 was found essential in controlling ERK sig-
naling in dMSNs, but its ablation did not prevent ERK activation in ChIs.
Moreover, striatal injection of LV-shRNA/Ras-GRF1 attenuated dyskinesia
development and ERK-dependent signaling, whereas LV-shRNA/Ras-GRF2 was
without effect, ruling out the involvement of Ras-GRF2 in LID expression.
Accordingly, Ras-GRF1 but not Ras-GRF2 striatal gene-knockdown reduced
L-DOPA-induced GABA and glutamate release in the substantia nigra pars
reticulata, a neurochemical correlate of dyskinesia. Finally, inactivation of
Ras-GRF1 provided a prolonged anti-dyskinetic effect for up to 7 weeks and
significantly attenuated symptoms in animals with established LID. Interpreta-
tion: Our results suggest that Ras-GRF1 is a promising target for LID therapy
based on Ras-ERK signaling inhibition in the striatum.
Introduction
L-DOPA-induced dyskinesia (LID) is one of the unwanted
and debilitating motor side effects ensuing from pro-
longed treatment with L-DOPA, the gold standard for the
symptomatic treatment of Parkinson’s disease (PD).1
Indeed, the majority of PD patients develop abnormal
involuntary movements (AIMs) within 5–10 years of L-
DOPA therapy.2 LID is still a significant clinical problem
since no truly effective treatment has been developed so
662 ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Figure 1. LID profile and ERK activation in dMSNs and ChIs during chronic L-DOPA administration. (A) Experimental design 1: 2 weeks after 6-
OHDA lesion, different groups of C57BL/6 mice were treated with L-DOPA: one group (n = 8) received an acute dose (3 mg/kg, 1 day) of L-DOPA
(hereinafter 1 day) and was perfused 20 min thereafter without performing AIMs; one group (n = 11) was treated with a 9 days protocol
(hereinafter 9 days) (days 1–3, 3 mg; days 4–6, 6 mg; days 6–9, 12 mg/kg) and lastly, two groups after the 9 days protocol underwent a
dyskinesia maintenance protocol consisting of twice a week injections (12 mg/kg L-DOPA plus 12 mg/kg of benserazide) for either 2 weeks
(n = 11) or 4 weeks (n = 11). For each time point, a small group of mice (n = 3) was treated with saline as internal control for subsequent
postmortem analysis. (B) Temporal profiles of all groups throughout the 9 days, 2 weeks, and 4 weeks protocol expressed as a sum of Axial,
Limb, and Orolingual AIMs (ALO AIMs) are shown. No differences in dyskinesia expression levels were found amongst groups in either the initial
9 days period (P = 0.259) or throughout the maintenance period (2 weeks vs. first 2 weeks of 4 weeks P = 0.577; vs. last 2 weeks of 4 weeks
P = 0.238). (C) Pearson’s correlation index revealed a positive, linear correlation between pERK levels in dMSNs and AIMs in the 9 days, but not
in the 4 weeks group (9 days: r = 0.802, P < 0.05; 4 weeks: r = 0.084, P = 0.878). (D) Representative micrographs of ERK1/2 immunoreactivity
(pERK) in the dorsolateral part of the striatum after completion of different L-DOPA treatments (1 day, 9 days and maintenance protocol). Scale
bar 30 lm. (E) Quantification of pERK levels observed in all L-DOPA-treated groups with statistical difference between 1 day and 9 days protocol
(one way ANOVA, treatment effect F(4, 38) = 20.884, P < 0.0001, Tukey’s post hoc 1 day vs. 9 days P < 0.05). (F) Immunofluorescent
micrographs of ERK activation in the dMSNs: pERK (green), DR1 (red) and NeuN (blue) cells in dorsal striatal. Scale bar 20 lm. Small insets of split
channels of pERK and DR1-positive cells are also reported. (G) Quantification of pERK-positive cells in D1R-positive and -negative cells, with
statistical difference after 1 day and 9 days protocol (one way ANOVA, treatment effect F(3, 34) = 8.2302, P < 0.001 Tukey’s post hoc 1 day vs.
9 days P < 0.001). (H) Immunofluorescent micrographs of ERK activation in cholinergic interneurons: pERK (green), ChAT (red) and NeuN (blue)
cells. Scale bar 30 lm. Small insets of split channels of ChAT and pERK-positive cells are also reported. (I) A raise of pERK levels was observed in
ChIs after 9 days (Kruskal–Wallis Test P < 0.0001; Mann–Whitney Test 1 day vs. 9 days, 2 weeks and 4 weeks P < 0.01) and persisted through
the prolonged administration of L-DOPA (Mann–Whitney Test 9 days vs. 2 weeks P = 0.124, 9 days vs. 4 weeks P = 0.787, 2 weeks vs. 4 weeks
P = 0.916). *P < 0.05, **P < 0.0.01, ***P < 0.001. LID, L-DOPA-induced dyskinesia; L-DOPA, L-3,4-dihydroxyphenylalanine; 6-OHDA,
6-hydroxydopamine; AIMs, abnormal involuntary movements.
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far. Besides the classical pharmacological approach target-
ing neurotransmitter receptors, accumulating evidence
from animal models supports a causative role for dysreg-
ulated D1 receptor intracellular signaling in striatal med-
ium-sized spiny neurons of the direct pathway (dMSNs).
These observations have opened new perspectives for
innovative therapeutic approaches against LID, based on
the inhibition of either the canonical PKA/DARPP-32 cas-
cade or the non-canonical Ras-ERK and mTOR path-
ways.3–11
The Ras-ERK cascade is an evolutionarily conserved
neuronal pathway involved in several survival processes
and an important regulator of behavioral plasticity.12–19
Its sustained activation leads to synaptic rearrangements
requiring de novo gene expression and protein synthe-
sis. In striatal cells, glutamate (GLU) and dopamine
receptors interact and provide a route to ERK activa-
tion.20–24 Importantly, in animal models of PD, includ-
ing the unilaterally 6-hydroxydopamine (6-OHDA)
lesioned rodent and the 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP)-treated non-human primate
(NHP), the supersensitivity of dopamine D1 receptors
leads to aberrant ERK activation in response to L-
DOPA, which correlates with LID severity.3–5,25,26 In
particular, our recent study indicated that Ras-GRF1, a
Ras activator (Ras guanine-nucleotide exchange factor,
Ras-GEF) expressed only in mature neurons of the cen-
tral nervous system, is necessary for the integration of
GLU and dopamine signaling that leads to ERK activa-
tion.23 Importantly, Ras-GRF1 specifically controls
downstream ERK signaling in a neurotrophin-indepen-
dent manner, suggesting that its inhibition would only
affect plasticity-related ERK signaling without altering
cell survival mechanisms. Consistently, Ras-GRF1 abla-
tion by conventional gene targeting27 does not affect
the ability of 6-OHDA to deplete dopamine-producing
cells but strongly attenuates ERK activation and AIMs
appearance in the rodent lesion model of LID.28 Nota-
bly, whilst ERK activity is required in all striatal cells to
induce long-term potentiation (LTP), Ras-GRF1 is nec-
essary only in striatal dMSNs, that is, those cells more
directly implicated in LID.11 Moreover, attenuation of
Ras-GRF1 and ERK signaling in the NHP model of PD
results in a strong reduction in dyskinetic symptoms
without compromising the antiparkinsonian effect of L-
DOPA, providing a more clinically valuable approach
via targeting Ras-ERK, which may ameliorate this path-
ological condition.28
A recent study showed that in Pitx3-deficient mice, a
genetic model of PD, the abnormal activation of ERK
surprisingly diminishes in MSNs but increases in the
large aspiny cholinergic interneurons (ChIs), upon con-
tinuous administration of L-DOPA.29 In addition, in a
subsequent study Won and colleagues demonstrated
that selective depletion of striatal ChIs via Cre-depen-
dent viral expression of the diphtheria toxin A signifi-
cantly attenuated LID without affecting the therapeutic
efficacy of L-DOPA.30 This evidence prompted us to
investigate in the first part of our work whether inter-
mittent but prolonged administration of high doses of
L-DOPA could lead to different ERK activation profiles
in dMSNs and ChIs and whether this activation in cho-
linergic interneurons is somehow regulated by Ras-
GRF1. Our previous observation that Ras-GRF1 inhibi-
tion in the brain only leads to ~50% reduction in
AIMs could indeed suggest that other factors may regu-
late striatal ERK activity in response to L-DOPA,
including a potentially Ras-GRF1-independent ERK acti-
vation in ChIs. Moreover, Ras-GRF2, a close homolog
of Ras-GRF1 in the striatum, may be an additional fac-
tor controlling ERK activity in dyskinesia. To address
this point in the second part of the work, we took
advantage of short hairpin RNA sequences (shRNA)
technology to specifically target the dorsolateral stria-
tum, a key area involved in the development of dyski-
netic movements to obtain striatal-specific gene
knockdown of Ras-GRF1 and Ras-GRF2. We then ana-
lyzed the behavioral consequences of these genetic
manipulations in the development of dyskinesia and
their molecular and neurochemical correlates. Finally,
we analyzed the possibility of reversing an already
established dyskinetic state.
Our findings showed that a sustained activation of
ERK is present in both dMSNs and ChIs after 4 weeks of
intermittent high doses of L-DOPA but in ChIs this event
is Ras-GRF1 independent. In addition, only Ras-GRF1,
but not Ras-GRF2 was critically involved in the develop-
ment of LID and in the correlated molecular changes.
Importantly, Ras-GRF1 silencing had a long-lasting thera-
peutic effect, up to 7 weeks and was also effective in alle-
viating established dyskinesia, demonstrating the potential
as a therapeutic intervention.
Material and Methods
For detailed description of material and methods see Data
S1.
Animals
In this study, we used the following: (1) C57BL/6 male
mice (Charles River Laboratories, Calco, Italy); (2) Ras-
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GRF1 KO males and their littermates.27 All experimental
animal procedures were conducted according to the EU
Directive 2010/63/EU and to experimental animal licenses
of the Fondazione San Raffaele del Monte Tabor and
University of Ferrara approved by the Italian Ministry of
Health and the local authorities.
Figure 2. Reduced ERK signaling in dMSNs but not ChIs population in Ras-GRF1 KO mice. (A) Immunofluorescent photomicrographs of ERK
activation in the dMSNs: pERK (green), DR1 (red) and NeuN (blue) cells in dorsal striatal area of WT and Ras-GRF1 KO mice after the 4 weeks
regimen of L-DOPA. Scale bar 20 lm. (B) pERK-positive cells colocalizing with D1R-positive cells were counted, with statistical difference between
WT and Ras-GRF1 KO mice (Independent-samples t-test, P < 0.001). (C) Immunofluorescent micrographs of acetyl-histone H3 activation (pAcH3)
in the dMSNs: pAcH3 (green), DR1 (red) and NeuN (blue) cells in dorsal striatal area of WT and Ras-GRF1 KO mice after the 4 weeks protocol of
L-DOPA. Scale bar 20 lm. (D) pAcH3-positive cells colocalizing with D1R-positive cells were counted, with statistical difference between WT and
Ras-GRF1 KO mice (Independent-samples t-test, P < 0.05). (E) Immunofluorescent micrographs of ERK activation in ChIs: pERK (green), ChAT (red)
and NeuN (blue) cells in dorsal striatal area of WT and Ras-GRF1 KO mice after 4 weeks regimen of L-DOPA. Scale bar 20 lm. (F) pERK-positive
cells colocalizing with ChAT-positive cells were observed, without statistical difference between WT and Ras-GRF1 KO mice (Independent-samples
t-test, P = 0.415). (G) Immunofluorescent micrographs of AcH3 activation in the ChIs: pAcH3 (green), ChAT (red) and NeuN (blue) cells in dorsal
striatal area of WT and Ras-GRF1 KO mice after the 4 weeks regimen of L-DOPA. Scale bar 20 lm. (H) pAcH3-positive cells colocalizing with
ChAT-positive cells were observed, without statistical difference between WT and Ras-GRF1 KO mice (Independent-samples t-test, P = 0.295).
Data are mean ! SEM of 8–10 animals for each group. *P < 0.05, ***P < 0.001.
Figure 3. Ras-GRFs-specific gene silencing in vitro and in vivo. Ras-GRF1 and Ras-GRF2 residual protein expression levels in neurons were
determined by Western blotting 48 h after LVs infection with three different shRNA cassettes (Seq 3, 2, 1 for (A) Ras-GRF1 and Seq 1,2,3 for (C)
Ras-GRF2) or the relative control sequence (Seq Ctr). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (B and
D) Quantification of three independent experiments showed that all sequences were able to reduce the expression of Ras-GRF proteins. (E) For
in vivo delivery, Seq 1 of sh-Ras-GRF1 and Seq 3 of sh-Ras-GRF2 were injected in striatum of wild type mice. Representative immunoblots of p140
Ras-GRF1 and p135 Ras-GRF2 are shown. (F) Densitometry analysis demonstrated that p140 Ras-GRF1 was reduced by sh-Ras-GRF1 (one way
ANOVA, main effect F(2, 9) = 10.517, P < 0.01, Bonferroni’s post hoc sh-Ctr vs. sh-Ras-GRF1 P < 0.01) without alterations in Ras-GRF2 protein
levels (Bonferroni’s post hoc sh-Ctr vs. sh-Ras-GRF2 P = 1.000). Similarly, p135 Ras-GRF2 was reduced by sh-Ras-GRF2 expression (main effect F
(2, 9) = 5.45, P < 0.05, Bonferroni’s post hoc sh-Ctr vs. sh-Ras-GRF2 P < 0.05) with no variation in Ras-GRF1 protein levels (Bonferroni’s post hoc
sh-Ctr vs. sh-Ras-GRF1 P = 0.282). (G) Immunoreactivity to both anti-phospho-ERK and anti-ERK antibodies in striata of sh-Ras-GRF1, sh-Ras-GRF2
and sh-Ctr injected mice. (H—I) Quantification of normalized p44 and p42 bands intensities revealed no changes in either protein levels or basal
phosphorylation state of ERK1/2. *Non-specific band. *P < 0.05, **P < 0.0.01.
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shRNA constructs and LV production
Three shRNA constructs were probed against Ras-GRF1
and Ras-GRF2 genes in primary cultures. The sequence
targeting the Ras-GEF region of Ras-GRF1 (sequence 1)
and PH domain of Ras-GRF2 (sequence 3) were used
in vivo. The Vesicular stomatitis virus (VSV) pseudotyped
third-generation lentiviral vectors (LVs) were produced as
previously described.31,32
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Stereotaxic Surgery and L-DOPA treatments
6-OHDA lesion
Unilateral 6-OHDA MFB lesions were performed as
described in Fasano et al.28
LV-shRNA injections
Two weeks post-6-OHDA lesions, mice with confirmed
ipsilateral rotations received unilateral striatal injections
(2 9 1 lL) of LVs as described in Fasano et al.28
L-DOPA administration
L-DOPA (Sigma Aldrich, Milan, Italy) was injected
accordingly to the following protocols: (1) daily injection
of 3 (day 1–3), 6 (day 4–6) or 12 (day 7–9) mg/kg in
combination with benserazide (Sigma-Aldrich) (12 mg/
kg) in the 9 days protocol; (2) twice a week 12 mg/kg
with 12 mg/kg benserazide in the maintenance protocol
of 4 and 7 weeks and in the reversal protocol of 4 weeks
(experimental design 1, 4, and 5, respectively). Mice not
treated with L-DOPA received an equivalent volume of
Figure 4. Striatal-specific gene knockdown of Ras-GRF1 or Ras-GRF2 does not impact on basal motor behavior of 6-OHDA lesioned mice. (A)
Experimental design 2: 2 weeks after 6-OHDA lesion mice performed spontaneous rotations test and were split in four groups, injected with sh-
Ras-GRF1, sh-Ras-GRF2 and sh-Ctr, respectively. Three weeks post-shRNA injection, mice performed spontaneous rotations, rotarod and drag
test. (B) Spontaneous full rotations were found equivalent among the experimental groups (one way ANOVA, F(3, 35) = 0.282, P = 0.838). (C)
Motor learning during 5 days on the rotarod was measured. A significant effect of training but not of treatment was observed in sh-Ras-GRF1
and sh-Ctr groups (Repeated measures ANOVA, F(1, 17) = 56.336, P < 0.0001). Similarly, sh-Ras-GRF2 and sh-Ctr mice displayed only a
significant effect of training (Repeated measures ANOVA, F(1, 17) = 30.073, P < 0.0001). (D) Akinesia was evaluated using drag test. On day 1,
the number of steps of the contralateral forepaw was significantly less than the one performed with the ipsilateral forepaw in all experimental
groups (Paired-samples t-test, sh-Ras-GRF1: t(8) = "11.300, P < 0.0001; sh-Ctr: t(9) = "8.899, P < 0.0001; sh-Ras-GRF2: t(9) = "5.349,
P < 0.001; sh-Ctr: t(9) = "5.365, P < 0.0001). On the subsequent test on day 5, the number of contralateral steps continued to be significantly
lower than the one of ipsilateral steps in all groups (Paired-samples t-test, sh-Ras-GRF1: t(8) = "5.635, P = 0.001; sh-Ctr: t(9) = "12.825,
P < 0.0001; sh-GRF2: t(9) = 5.312, P < 0.001; sh-Ctr: t(9) = 4.589, P < 0.001). Data are mean ! SEM of 9–11 animals for each group.
***P < 0.001, ****P < 0.0001.
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Saline. Both drugs were injected i.p. in a total volume of
10 mL/kg body weight.
Behavioral analysis, in vivo microdialysis and postmor-
tem examination were performed as described in refs
[28,33–36].
Figure 5. Striatal downregulation of Ras-GRF1 but not Ras-GRF2 is able to attenuate LID expression. Four weeks after sh-injection, 9 days
L-DOPA protocol was administered and AIMs were daily scored. (A) A gradual development of dyskinesia was observed (repeated measure
ANOVA, time effect, F(2.182, 47.999) = 29.703, e = 0.273 P < 0.0001). However, sh-Ras-GRF1 mice developed dyskinesia to a lesser extent
in comparison to their controls (repeated measure ANOVA, shRNA effect, F(1, 22) = 6.944, P < 0.05), with the difference becoming evident
on day 4 of L-DOPA exposure and persisting till day 9 (P < 0.05). (B) The analysis of the area under curve (AUC) of AIMs score confirmed
this reducing effect of sh-Ras-GRF1 (mean ! SEM) (Independent-samples t-test: t(22) = 2.618, P < 0.05). (C) Sh-Ras-GRF1 expression lessened
the Limb and Axial components of AIMs in comparison to sh-Ctr mice (ANOVA, shRNA effect, P < 0.05) while the Orolingual subtype was
found only almost significantly different from sh-Ctr animals (ANOVA, shRNA effect, P = 0.06). (D) Sh-Ras-GRF2 injected mice showed rising
dyskinesia levels over time but the intensity displayed was equal to sh-Ctr mice (repeated measure ANOVA, shRNA effect, F(1, 20) = 0.497,
P = 0.489). (E) Analysis of AUC (mean ! SEM) (Independent-samples t-test: t(20) = "0.773, P = 0.448) and (F) individual components of ALO
AIMs in Ras-GRF2 silenced mice were similar to those observed in sh-Ctr animals (ANOVA, shRNA effect, P > 0.05). Data are mean ! SEM
of 9–11 animals for each group. *P < 0.05.
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Results
Prolonged and intermittent L-DOPA
treatment in dopamine-depleted mice
induces persistent and long-lasting ERK
activation in both dMSNs and ChIs
In order to define ERK activation profile in dMSNs and ChIs
in LID, we first applied different protocols of L-DOPA
administration in 6-OHDA lesioned mice: (1) 1 day acute
protocol; (2) 9 days dose-escalating protocol and (3) 9 days
protocol followed by LID maintenance protocol of either 2
or 4 weeks (Fig. 1A). In the acute protocol, mice were
injected with 3 mg/kg of L-DOPA and 20 min after they
were perfused to detect molecular changes without scoring
AIMs. In the 9 days protocol, mice developed a clear dyski-
netic state that remained stable over 4 weeks (Fig. 1B). A
correlation was found between ERK1/2 immunoreactivity
(pERK levels) in dMSNs and axial, limb and orolingual
(ALO) AIMs at 9 days but not 4 weeks (Fig. 1C). In fact,
ERK activity in the dMSNs became maximal already after
acute L-DOPA challenge and remained high also after 9 days
of treatment in concomitance to an exacerbated dyskinetic
behavior. However, we detected only a small but significant
decrease after 9 days of treatment in comparison to the
acute challenge that was not observed after the intermittent
administration of L-DOPA in the maintenance protocol
(Fig. 1D–G). In contrast, in ChIs, ERK activation was evi-
dent only after 9 days of L-DOPA administration (Fig. 1H
and I). The results thus far indicate that ERK activity
remains high in dMSNs in response to a prolonged but
intermittent L-DOPA administration and appears also in
ChIs only after a repeated challenge with L-DOPA.
Ras-GRF1 controls ERK signaling in dMSNs
but not in ChIs
As described earlier, Ras-GRF1 KO animals are signifi-
cantly less dyskinetic than controls and exhibit lower lev-
els of ERK activation and FosB/DFosB expression. This
evidence was not due to a different expression of Ras-
GRF1 in striatonigral MSNs but to the specific engage-
ment of Ras-GRF1 by D1 receptors.11,28
Thus, we next examined whether Ras-GRF1 may also
regulate ERK signaling in ChIs using the Ras-GRF1 KO
model. We found that pERK was significantly reduced in
dMSNs (Fig. 2A and B) but not in ChIs (Fig. 2E and F)
of Ras-GRF1 KO animals upon a 4 weeks dyskinesia
maintenance protocol. Similarly, downstream phosphory-
lation of acetyl-histone H3 (AcH3), also known to be
associated with LID but never measured in ChIs4,25 was
only attenuated in dMSNs (Fig. 2C and D) but not in
ChIs (Fig. 2G and H). These data strongly indicate that
Ras-GRF1 does not control ERK activity in ChIs of the
striatum, suggesting that other factors may regulate ERK
signaling in these cells.
Validation of LV-assisted gene knockdown
of Ras-GRF1 and Ras-GRF2
Ras-GRF2 is a close homolog of Ras-GRF1, and is
expressed, although to a lesser extent, in the striatum.23
To address the possibility that Ras-GRF2 could play a
role in LID, we used a sophisticated viral-mediated
approach to knockdown both Ras-GRF1 and Ras-GRF2
gene in striatal cells, in vitro and in vivo. Expression cas-
settes containing 3 distinct Ras-GRF1 and Ras-GRF2-spe-
Figure 6. Striatal-specific gene knockdown of Ras-GRF1 but not Ras-GRF2 reduces ERK phosphorylation and FosB/DFosB accumulation associated
with LID. (A) Photomicrographs of ERK1/2 immunoreactivity in the dorsal striatum of sh-Ctr and sh-Ras-GRF1 groups after 9 days L-DOPA or
Saline treatment. (B) Quantification of pERK-positive cells revealed a significant effect of L-DOPA in both shRNA injected groups in comparison to
saline (two way ANOVA, treatment effect, F(1, 29) = 41.890, P < 0.0001). However, a significant reduction of pERK was observed in sh-Ras-GRF1
mice (two way ANOVA, interaction genotype 9 treatment effect, F(1, 29) = 6.319, P < 0.05). (C) Pearson’s correlation index revealed a strong,
linear correlation between ERK levels and AIMS in both experimental groups (sh-Ctr: r = 0.935, P < 0.001; sh-Ras-GRF1: r = 0.914, P < 0.0001).
(D) Photomicrographs of pERK in sh-Ctr and sh-Ras-GRF2 groups after 9 days L-DOPA protocol. (E) Quantification of pERK-positive cells revealed a
significant effect of L-DOPA (two way ANOVA, treatment effect, F(1, 26) = 84.954, P < 0.0001) without difference between sh-Ctr and sh-Ras-
GRF2 mice (two way ANOVA, shRNA effect, F(1, 26) = 0.026, P = 0.874). (F) Pearson’s correlation index revealed a positive, linear correlation
between ERK levels and AIMS in both experimental groups (sh-Ctr: r = 0.850, P < 0.001; sh-Ras-GRF2: r = 0.895, P < 0.0001). (G)
Photomicrographs of FosB/DFos Bimmunoreactive cells in the dorsal striatum of sh-Ctr and sh-Ras-GRF1 groups after 9 days L-DOPA or Saline
treatment. (H) Ras-GRF1 knockdown significantly reduced FosB/DFosB accumulation (two way ANOVA, interaction genotype 9 treatment effect, F
(1, 29) = 4.402, P < 0.05). (I) A positive, linear correlation was found between FosB levels and AIMs in both experimental groups (sh-Ctr:
r = 0.931, P < 0.001; sh-Ras-GRF1: r = 0.921, P < 0.0001). (J) Photomicrographs of FosB/DFosB-immunoreactive cells in the dorsal striatum of
sh-Ctr and sh-Ras-GRF2 groups after 9 days L-DOPA or Saline treatment. (K) Equivalent levels of FosB/DFosB accumulation were induced by
L-DOPA treatment (two way ANOVA, treatment effect, F(1, 26) = 83.857, P < 0.0001) without difference between sh-Ras-GRF2 mice and their
controls (two way ANOVA, shRNA effect, F(1, 26) = 0.353, P = 0.557). (L) A positive, linear correlation was found between FosB levels and AIMs
in both experimental groups (sh-Ctr: r = 0.850, P < 0.001; sh-Ras-GRF2: r = 0.895, P < 0.0001). Scale bar 30 lm. Data are mean ! SEM of
9–11 animals for each group. *P < 0.05.
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cific short hairpin RNAs (shRNA) were transferred into
green fluorescent protein (GFP)-tagged LV in order to
test their inhibitory potential in neurons on p140Ras-GRF1
and p135Ras-GRF2, respectively. We prepared in vitro neu-
ronal cultures from newborn (P1) wild type mice, which
were subsequently infected with equal amounts of LV.
Then, cells were processed by Western blot analysis using
specific antibodies against Ras-GRF1 and Ras-GRF2 pro-
teins (Fig. 3A and C). All selected sequences were able to
reduce the expression of Ras-GRF proteins in comparison
with control sequence (hereinafter sh-Ctr). We selected
the most effective sequences, that is, sequence 1 of LV-
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shRNA/Ras-GRF1 (hereinafter sh-Ras-GRF1) and
sequence 3 of LV-shRNA/Ras-GRF2 (hereinafter sh-Ras-
GRF2), for further in vivo experiments (Fig. 3B and D
respectively). To confirm in vivo efficacy of the selected
shRNA sequences, we performed unilateral stereotaxic
injections of sh-Ras-GRF1, sh-Ras-GRF2 or sh-Ctr in the
motor striatum of wild type mice, and 3 weeks later,
protein content in dorsal striata was determined by Wes-
tern blot (Fig. 3E). Expression level of p140Ras-GRF1 was
reduced by sh-Ras-GRF1 with no alterations in Ras-
GRF2 levels. Similarly, sh-Ras-GRF2 significantly
decreased the expression level of p135Ras-GRF2 without
affecting Ras-GRF1 levels (Fig. 3F). The observed in vivo
reduction in p140 and p135 was likely to be an underes-
timation due to the significant presence of non-infected
cells in the tissue samples (see also Fig. 7). Importantly,
no changes in either ERK1/2 protein levels or basal phos-
phorylation were observed (Fig. 3G and H).
Ras-GRF1 and Ras-GRF2 gene knockdown
does not interfere with basal motor
behavior in 6-OHDA lesioned mice
Next, we asked whether Ras-GRF1 or Ras-GRF2 knock-
down could affect the course of 6-OHDA lesioning.
Mice were hemilesioned with 6-OHDA then sorted by
comparable levels of rotational behavior 2 weeks later,
and finally unilaterally injected with LVs in the dorsal
striatum. Three weeks later, lesion-induced motor deficits
were examined using spontaneous rotations, rotarod,
and drag test28,33 (Fig. 4A). All four shRNA groups
showed a similar number of spontaneous ipsilateral rota-
tions during a 10 min session, suggesting an equivalent
extent of 6-OHDA damage, regardless of the injected
short hairpins (Fig. 4B). Motor abilities were also evalu-
ated on the rotarod during a 5-days training protocol.
Latency to fall was similar in sh-Ras-GRF1, sh-Ras-GRF2
and sh-Ctr animals at day 1, and significantly increased
to the same extent in all groups at day 5, indicating a
significant effect of training (Fig. 4C). A marked reduc-
tion in stepping activity at the contralateral forepaw in
the drag test was observed in sh-Ras-GRF1, sh-Ras-GRF2
and sh-Ctr mice at both day 1 and day 5 of training,
demonstrating a uniform effect of 6-OHDA across
groups (Fig. 4D).
Ras-GRF1 but not Ras-GRF2 striatal silencing
attenuates LID
To evaluate whether specific knockdown of striatal Ras-
GRF1 and Ras-GRF2 would affect behavioral responses to
repeated L-DOPA treatment, we applied the 9 days
L-DOPA protocol.28 A gradual development of dyskinesia
in both sh-Ras-GRF1 and sh-Ctr injected animals was
observed. However, LID scores were significantly lower in
sh-Ras-GRF1 mice than in controls (Fig. 5A and B). Fur-
ther analysis indicated that in sh-Ras-GRF1 mice all AIMs
subtypes were weakened, confirming the prominent role
of Ras-GRF1 in LID development (Fig. 5C). On the con-
trary, time course and intensity of the L-DOPA response
in sh-Ras-GRF2 mice were similar to those observed in
control animals, ruling out the involvement of Ras-GRF2
in LID formation (Fig. 5D–F).
On day 10, mice were challenged with a final dose of
12 mg/kg of L-DOPA and transcardially perfused 20 min
later in order to analyze the involvement of Ras-GRF1
and Ras-GRF2 in the downstream signaling associated
with the severity of AIMs. Only sh-Ras-GRF1 mice
showed a significant reduction in ERK activation and
FosB/DFosB immunoreactivity (Fig. 6A, B, G and H)
whilst knockdown of Ras-GRF2 did not affect these
molecular changes (Fig. 6D, E, J and K). Furthermore,
positive correlations between the severity of AIMs and
ERK phosphorylation or FosB/DFosB accumulation were
observed (Fig. 6C, F, I, and L).
To confirm that reduction in ERK signaling was spe-
cific to silenced cells we examined the involvement of
Ras-GRF1 and Ras-GRF2 in the phosphorylation of
AcH3. Triple-labeling experiments showed that reduction
in AcH3 phosphorylation was only restricted to sh-Ras-
GRF1 silenced cells (Fig. 7A and B). Indeed, no
differences were found in non-infected cells of sh-Ctr and
sh-Ras-GRF1 mice though the percentage of infection was
similar in both groups and accounted for ~35% of cells
(Fig. 7C and D). Not surprisingly, sh-Ras-GRF2 silencing
did not alter AcH3 activation in L-DOPA-treated mice
(Fig. 7E–H). Altogether, these data not only confirm a
prominent role of Ras-GRF1 in LID formation and ERK
regulation in response to chronic L-DOPA but also rule
out an involvement of Ras-GRF2 in this process.
Ras-GRF1 but not Ras-GRF2 striatal
knockdown reduces L-DOPA-induced GABA
release in the substantia nigra
The alterations caused by Ras-GRF1 gene knockdown on
behavioral and cellular correlates of LID prompted us to
determine its possible impact on substantia nigra pars
reticulata (SNr) and globus pallidus (GP) neurochemical
changes after L-DOPA administration. Indeed, previous
work showed that an increase in c-Aminobutyric acid
(GABA) and glutamate (GLU) levels in the SNr but not
in the GP correlated with the intensity of dyskinesia.34,37
After the 9 days protocol, mice underwent dual probe
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Figure 7. Silencing of Ras-GRF1 in the striatum dampens the L-DOPA-induced phospho-acetylated histone H3. (A) Photomicrographs of pAcH3
(red), shRNA constructs (green) and NeuN (blue) in the dorsal striata of sh-Ras-GRF1 mice after the 9 days L-DOPA protocol. (B) A significant
reduction in pAcH3 was found in successfully silenced cells of mice treated with sh-Ras-GRF1 in comparison to sh-Ctr injected mice (two way
ANOVA, shRNA effect, F(1, 20) = 7.765, **P < 0.001). (C) PAcH3 quantification among non-infected neurons (sh-cells- no GFP) was instead
found equivalent in L-DOPA-treated mice (two way ANOVA, shRNA effect, F(1, 20) = 0.01, P = 0.980). (D) Percentage of sh-infected cells
counted on total NeuN-positive neurons was found comparable in both experimental groups (two way ANOVA, shRNA infection effect, F(1,
20) = 0.666, P = 0.424). (E) Equivalent photomicrographs of pAcH3 in sh-Ras-GRF2 mice after the 9 days L-DOPA protocol. (F) Identical activation
of AcH3 was found in successfully silenced cells of mice treated with sh-Ras-GRF2 in comparison to sh-Ctr injected mice (two way ANOVA,
shRNA effect, F(1, 20) = 0.024, P = 0.878). (G) PAcH3 quantification among non infected neurons (sh-cells- no GFP) was found equivalent in L-
DOPA-treated mice (two way ANOVA, shRNA effect, F(1, 20) = 0.342, P = 0.565). (H) Percentage of sh-infected cells counted on total NeuN-
positive neurons was found comparable in both experimental groups (two way ANOVA, shRNA infection effect, F(1, 20) = 0.010, P = 0.922).
Scale bar, 50 lm. Data are mean ! SEM of 10–11 animals for each group ** P < 0.001.
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microdialysis implantation and received a challenge of L-
DOPA 24 h later: GABA and GLU release was monitored
simultaneously with AIMs scoring (Fig. 8A). Sh-Ras-
GRF1 mice showed less severe dyskinesia in response to
L-DOPA than controls (Fig. 8B), this effect being paral-
leled by a milder increase in GABA levels in SNr
(Fig. 8D). Conversely, sh-Ras-GRF2 animals were as dys-
kinetic as sh-Ctr mice (Fig. 8C) and, consistently, no dif-
ference in the extent of the GABA levels rise was observed
between the two groups (Fig. 8E). Moreover, GLU over-
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flow in the SNr of sh-Ras-GRF1 mice did not show any
increase over time, contrary to what can be observed in
sh-Ctr mice (Fig. 8F). On the other hand, both sh-Ras-
GRF2 mice and sh-Ctr animals showed a significant
increase in the GLU overflow over time (Fig. 8G). Finally,
no changes in either GABA or GLU levels were detected
in the GP of any group of mice in response to L-DOPA
(Fig. 8H–K).
These data clearly indicate that Ras-GRF1 inhibition
and the associated attenuation of LID are linked to signif-
icant neurochemical changes in the substantia nigra.
Gene knockdown of Ras-GRF1 provides long-
term beneficial effects on LID
Finally, we investigated whether Ras-GRF1 gene knock-
down could either attenuate LID in a prolonged L-DOPA
protocol or could affect already established dyskinetic
state. First, we applied the 9 days protocol followed by
twice a week L-DOPA treatment for 7 weeks (Fig. 9A): as
expected, sh-Ras-GRF1 silenced animals showed a lower
progression of LID that was maintained throughout the
experiment (Fig. 9B and C). The beneficial effect was
confirmed on the last day of treatment showing a reduced
and shortened ALO profile (Fig. 9D). Second, we treated
6-OHDA-lesioned mice with L-DOPA accordingly to our
9 days protocol. Then mice were equally balanced in two
groups following an unbiased design and submitted to
intrastriatal LVs injection (Fig. 9E). After a short recovery
period mice were then challenged with 12 mg/kg of
L-DOPA twice a week for 4 weeks. The dyskinetic profile
before LVs injection was the same in both groups. How-
ever, 3 weeks post-LVs injection, AIMs were significantly
attenuated in sh-Ras-GRF1 mice and were comparable to
the extent observed in the initial phase of the treatment
(Fig. 9F–H).
These data demonstrated that Ras-GRF1 inhibition not
only provides a long-term beneficial therapeutic effect in
attenuating LID but also can significantly ameliorate a
severe dyskinetic state.
Discussion
The Ras-ERK cascade appears to be particularly promis-
ing for the treatment of LID since its involvement has
been confirmed by various independent studies. However,
ERK signaling is not only involved in plasticity processes,
like MSNs dysregulation in LID, but also in cell survival
mechanisms. Therefore, identification of key components
of this signaling pathway selectively involved in LID
would be highly advantageous since the repeated use of
available MEK inhibitors in PD patients may result in
intolerable side effects, including an exacerbation of dopa-
mine cell loss in the SN.38
Here we found that an acute dose of L-DOPA was able
to trigger maximal ERK activation in dMSNs and dyski-
nesia appearance, while a prolonged and intermittent
drug administration resulted in a sustained ERK activity
in dMSNs and a stable dyskinetic behavior. Differently
from Ding and colleagues, we observed an engagement of
the ChIs upon chronic L-DOPA treatment not paralleled
by a concomitant ERK downregulation in dMSNs.29
These discrepancies are likely due to a different dose and
regimen of L-DOPA administration. Moreover, we did
not observe a reduction in ERK activation after 4 weeks
maintenance protocol as reported by Santini et al., in dys-
kinetic NHPs after 3 months of L-DOPA administration
likely for the same reasons.7 Nevertheless, we considered
the contribution of ERK signaling in these two cell popu-
lations. Thus, we explored the involvement of Ras-GRF1
in MSNs and ChIs activity using the Ras-GRF1-deficient
mice. Surprisingly, we found that Ras-GRF1 controls ERK
activity exclusively in dMSNs. Indeed in dopamine-
depleted striatum, untreated or acutely exposed to L-
DOPA, ERK signaling in ChIs is not altered, but increases
only upon repeated L-DOPA administration, in a Ras-
GRF1-independent manner. This finding may explain the
presence of residual dyskinetic symptoms in Ras-GRF1-
deficient mice, possibly due to the intact ERK activity in
ChIs. Thus, unlike dMSNs, where ERK activation upon
D1 and GLU receptor interplay requires Ras-GRF1,23 in
Figure 8. Ras-GRF1 reduces L-DOPA-induced GABA release in the substantia nigra. (A) Experimental design 3: after the 9 days L-DOPA protocol,
sh-Ctr, sh-Ras-GRF1 and sh-Ras-GRF2 dyskinetic mice underwent surgery for microdialysis probe implantation, and were challenged with L-DOPA
(12 mg/kg, i.p.) or saline 24 h later. Three baseline samples were collected before the time point 0, indicated with an arrow, corresponding to
L-DOPA i.p. injection. ALO AIMs were scored every 20 min over 120 min after L-DOPA administration. (B) A significant reduction in LID was
observed in L-DOPA-treated sh-Ras-GRF1 in comparison to sh-Ctr mice (two way ANOVA, shRNA effect F(1, 60) = 41.14, P < 0.05). (C)
Comparable levels of dyskinesia were observed in sh-Ras-GRF2 and sh-Ctr mice (two-way ANOVA, shRNA effect F(1, 114) = 3.445, P = 0.066).
(D) A significant reduction in GABA levels in SNr of L-DOPA-treated sh-Ras-GRF1 mice compared to sh-Ctr animals was observed (two-way
ANOVA, shRNA effect F(1, 81) = 29.82, P < 0.0001). (E) Equivalent levels of GABA in SNr were displayed by L-DOPA-treated sh-Ras-GRF2 and sh-
Ctr mice (two-way ANOVA, shRNA effect F(1, 126) = 1.927, P = 0.1675). (F) A reduction in GLU levels in SNr of L-DOPA injected sh-Ras-GRF1
mice compared to sh-Ctr group was found (two-way ANOVA, shRNA effect F(1, 81) = 4.074, P < 0.05). (G) In SNr of sh-Ras-GRF2 groups, GLU
levels were equally altered by L-DOPA treatment (two-way ANOVA, shRNA effect F(1, 108) = 0.7117, P = 0.4008). No relevant differences were
observed among groups for GABA (H and I) and GLU (J and K) levels in GP. Data are mean ! SEM of 6–12 animals. *P < 0.05.
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cholinergic cells the route of activation may be distinct
and the underlying mechanisms are yet to be elucidated.
Regardless of the exact mechanism controlling ERK
activity in ChIs, the reduction in ERK signaling in
dMSNs of Ras-GRF1 knockout and knockdown mice not
only correlates well with LID attenuation, but also con-
firms that blockade of Ras-GRF1 mediated signaling in
the dorsostriatal dMSNs provides a significant antidyski-
netic effect. However, the reduction in ERK activity
observed in Ras-GRF1-deficient dMSNs is not complete,
strongly suggesting the involvement of other factors. We
previously showed that a suboptimal dose of a MEK
inhibitor, SL327, could further reduce AIMs (up to 80%)
in Ras-GRF1 KO mice indicating that LID symptoms are
largely ERK dependent.28 For this reason, we hypothe-
sized the involvement of a close Ras-GRF1 homolog, Ras-
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GRF2. Unfortunately, our results provide compelling
behavioral, histochemical and neurochemical evidence
excluding its involvement in this process. This finding is
in line with the idea that despite their homology, Ras-
GRF1 and Ras-GRF2 display non-overlapping functional
roles.39
In addition to the molecular control of ERK at the
input level, that is, through Ras-GRF1 or other Ras-GEFs,
other downstream mechanisms have been involved in
LID. The first is the D1R mediated cAMP-PKA-DARPP32
cascade whose activation leads to ERK enhancement.4,22
The second, attractive pathway relies on the protein tyro-
sine phosphatase Shp-2 that also acts downstream to D1R
to control ERK activity, both in normal and dyskinetic
states.9,40
Future work will assess the potential contribution of
these two additional pathways in the Ras-GRF1-indepen-
dent regulation of ERK activity in LID. Finally, it is
important to note that additional levels of ERK, histone
H3 and/or DFosB regulation could be achieved through
other mechanisms, either involving mGluR5/PLC/PKC
modulation, cAMP/PKA/DREAM-dependent transcrip-
tional repression or NO/cGMP signaling as recently
described.10,41,42
One final important point refers to the poorly explored
relationship between changes in striatal cell signaling and
neurotransmitter release. Previous in vivo microdialysis
studies in dyskinetic rats and mice have shown that AIMs
appearance following a dyskinetogenic dose of L-DOPA is
associated with an increase in GABA and GLU levels in
SNr.34,37,43 These changes are consistent with dMSNs
hyperactivity since they are prevented by intrastriatal per-
fusion with a D1 receptor antagonist.43 In line with these
findings, silencing Ras-GRF1 in dMSNs caused LID atten-
uation and no surge in nigral amino acid levels upon
L-DOPA challenge. Interestingly, however, we found that
also perfusion with a D1 receptor antagonist in the SNr
of dyskinetic rats provides attenuation of both LID and
the accompanying increase in nigral GABA.43 Consis-
tently, D1 receptor agonist induced [3H]-GABA release
was found to be upregulated in ex vivo nigral slices
obtained from dyskinetic rats.44 This suggests that also ni-
gral D1 receptors contribute to LID, and that the L-DOPA
induced increase of nigral GABA release might be
achieved through activation of both striatal postsynaptic
D1 receptors located on dMSNs and nigral D1 receptors
located on striato-nigral GABA afferents. Silencing Ras-
GRF1 in dMSNs would therefore prevent up-regulation
of both striatal and nigral D1 receptors, making L-DOPA
unable to elevate nigral GABA release.
LID is a chronic disorder and, once established, it will
be affecting PD patients throughout their life. Thus, in
order to translate our initial findings in clinically relevant
observations, we investigated two important aspects asso-
ciated with the Ras-GRF1 role in this disorder. First, we
confirmed that Ras-GRF1 attenuation ameliorates LID
symptoms also in the maintenance phase, up to 7 weeks
of chronic L-DOPA treatment. Second, we found that
already established dyskinesia could be significantly atten-
uated by Ras-GRF1 knockdown. These data strongly sup-
port the therapeutic potential of Ras-GRF1 modulation
and are in line with our previous work on the NHP
model.28
Altogether, our work provides important insights for a
better interpretation of the molecular mechanisms under-
lying LID and also relevant information for devising suc-
cessful therapeutic approaches based on intracellular
signaling inhibition in the striatum.
Figure 9. Ras-GRF1 inhibition reduces appearance of dyskinesia over prolonged L-DOPA treatment and also alleviates its expression. (A)
Experimental design 4: 3 week post-sh-injection, mice underwent first the 9 days L-DOPA protocol followed by 7 weeks maintenance protocol
consisting of twice a week injections (12 mg/kg L-DOPA plus benserazide). (B) Daily scoring of AIMs during the 9 days protocol showed a
significant reduction in dyskinetic behavior in sh-Ras-GRF1 silenced mice over time (repeated measure ANOVA, shRNA effect, F(1, 22) = 15.163,
P < 0.001, time effect, F(8, 176) = 34.263, P < 0.0001; Independent sample T-test, from day 4 to day 9 P < 0.01). This effect persisted over
7 weeks of treatment (repeated measure ANOVA, shRNA effect, F(1, 22) = 41.585, P < 0.001, independent sample T-test, all days of
maintenance P < 0.001). (C) The analysis of the area under curve (AUC) of AIMs score during the maintenance protocol confirmed the protective
effect of sh-Ras-GRF1 (mean ! SEM) (Independent-samples t-test: t(22) = 5.360, P < 0.001). (D) Time profile of the sum of ALO AIMs on the last
day (day 56) of treatment. A significant effect of shRNA, F(1, 22) = 19.412, P < 0.001 and time, F(6, 132) = 141.383, P < 0.001 was found. (E)
Experimental design 5: after the 9 days L-DOPA protocol, dyskinetic mice were divided in two equivalent groups and subsequently underwent
surgery for LVs-injection in the dorsal striatum. Few days later, mice were subjected to a dyskinesia maintenance protocol of 4 weeks (12 mg/kg
of L-DOPA, twice a week). (F) the expression of LID upon 9 days protocol was equivalent in both groups before LVs injection. However, during
the maintenance protocol, sh-Ras-GRF1 showed a significantly reduction in dyskinetic behavior (repeated measure ANOVA, shRNA effect, F(1,
22) = 6.7733, P < 0.05, independent sample T-test, from day 27 to day 41 P < 0.05. (G) The analysis of the area under curve (AUC) of AIMs
score confirmed the antidyskinetic effect of sh-Ras-GRF1 (mean ! SEM) (independent-samples t-test: t(22) = 2.564, P < 0.05). (H) Time profile of
the sum of ALO AIMs on the last day (day 41) of treatment. A significant effect of shRNA, (F(1, 22) = 5.991, P < 0.05) and time, (F(7,
154) = 42.073, P < 0.05) was found. Data are mean ! SEM of 10–12 animals for each group. *P < 0.05, **P < 0.01, ***P < 0.001.
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